The development of E3 inhibitors functioning in ubiquitin-positive aggregate formation could suppress neurodegenerative diseases, and since M1-ubiquitin can only be produced by LUBAC, it is an important therapeutic target. Here, UBA52 is linked to neurodegenerative disease.